The test is designed to detect clinically relevant genomic alterations — including somatic mutations, microsatellite instability, and viral DNA from ctDNA — in blood.
The firm signed four new distribution deals to spread its products into more than a dozen new markets.
Nikon will distribute OptraScan's whole-slide imaging scanners, as well as its integrated telepathology, and AI- and machine learning-based analytics solutions.
OncoDNA anticipates a strong increase in the use of OncoDNA profiling products in Europe with the partnerships with Gammaray and AMS.
The deal covers Cancer Genetics' microarray-based Tissue of Origin test, which analyzes 2,000 individual tumor genes to help identify a tumor's origin.
The three-year extension increases the minimum purchase commitments for the Unyvero system, resulting in an increase in potential revenues of €30 million to Curetis.
Immunoscore Colon predicts the risk of recurrence in patients with early-stage colon cancer and guides oncologists in decisions about therapies for stage II and III colon cancers.
The tests are based on a technology that uses Fourier transform infrared spectroscopy and a proprietary technique that analyzes spectrometer test results.
TSG is a wholly owned subsidiary of Ascendis Medical and supplies diagnostic laboratory equipment and consumables to pathology laboratories.
Lucence's test are designed to detect DNA fragments shed by a tumor into the blood and target the most common cancers in Asia such as lung cancer.